Milica Radisic
CEO

Quthero develops a bioengineered wound management gel utilizing its proprietary Q-peptide technology, derived from Angiopoietin-1, to enhance cell migration and collagen deposition for faster healing. This gel effectively reduces inflammation and improves skin quality in post-aesthetic procedures, addressing the need for efficient wound care in dermatology.
Raised to date
$1.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

CEO
Post-aesthetic procedures often result in inflammation, redness, swelling, bruising, and slow healing, impacting patient satisfaction and recovery time. Current wound-healing solutions may not adequately address these issues or fully support skin regeneration.
Quthero develops bioengineered regenerative therapies, based on its proprietary Q-peptide technology derived from Angiopoietin-1, to accelerate wound healing and improve skin quality. The Q-peptide promotes cell migration, collagen deposition, and blood vessel stabilization while reducing inflammation. Quthero's products are designed for post-aesthetic procedures to minimize redness, swelling, and bruising, leading to faster recovery and enhanced skin texture.
Quthero's products target individuals undergoing aesthetic procedures, dermatologists, and medical professionals seeking advanced wound-healing solutions.